Soluble tumorigenicity suppression protein (sST2) as a possible biomarker in patients with acute coronary syndrome
https://doi.org/10.21886/2712-8156-2023-4-2-7-17
Abstract
Many prognostic tools have been developed over the past decades, however, the identification of biomarkers that can predict the risk of acute coronary disease and its associated complications, especially heart failure, remains a promising direction, the study of which will provide understanding of the pathophysiology of this disease and identify new targets for therapy. One such potential biomarker is soluble suppression of tumorigenicity 2, which is able not only to predict left ventricular remodeling and poor clinical outcome among patients with acute coronary syndrome, but also to complement other well-established cardiac biomarkers such as natriuretic peptides and cardiac troponins. At the same time, if a number of separate but often converging pathways are involved in the pathogenesis of acute coronary disease, then multimarker approaches with various combinations of new cardiac biomarkers and their continuous assessment are likely to improve the prediction of cardiac risk and long-term outcomes.
About the Authors
V. I. Fetisova
Kuban State Medical University; S.V. Ochapovsky Regional Clinical Hospital №1
Russian Federation
Russian Federation
Valeria I. Fetisova - postgraduate student of the Department of Therapy No. 1 of the Kuban State Medical University, cardiologist of the Emergency cardiology department No. 2 of the Scientific Research Institute - Regional Clinical Hospital No.1 named after. prof. S.V. Ochapovsky.
Krasnodar
A. M. Namitokov
Kuban State Medical University; S.V. Ochapovsky Regional Clinical Hospital №1
Russian Federation
Russian Federation
Alim M. Namitokov - Cand. Sci. (Med.), Head of Emergency cardiology department No. 2 of the Scientific Research Institute - Regional Clinical Hospital No.1 named after. prof. S.V. Ochapovsky.
Krasnodar
I. V. Gilevich
Kuban State Medical University; S.V. Ochapovsky Regional Clinical Hospital №1
Russian Federation
Russian Federation
Irina V. Gilevich - Cand. Sci. (Med.), Assistant of the Department of Oncology with the course of thoracic Surgery of the Kuban State Medical University, Head of the Laboratory of the Scientific Research Institute – Regional Clinical Hospital No.1 named after. prof. S.V. Ochapovsky.
Krasnodar
E. D. Kosmacheva
S.V. Ochapovsky Regional Clinical Hospital №1
Russian Federation
Russian Federation
Elena D. Kosmacheva - Dr. Sci. (Med.), Professor, Scientific Research Institute – Regional Clinical Hospital No.1 named after. prof. S.V. Ochapovsky.
Krasnodar
References
1. Frioes F, Louren?o P, Laszczynska O, Almeida PB, Guimaraes JT, Januzzi JL, et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol. 2015;104(6):491-9. doi: 10.1007/s00392-015-0811-x
2. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117(15):1936-44. doi: 10.1161/CIRCULATIONAHA.107.728022
3. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109(18):2186-90. doi: 10.1161/01.CIR.0000127958.21003.5A
4. Liu X, Hu Y, Huang W, Zhang G, Cao S, Yan X, et al. Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI. Int Heart J. 2019;60(1):19-26. doi: 10.1536/ihj.18-020
5. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012;58(1):257-66. doi: 10.1373/clinchem.2011.173369
6. Zhang Q, Hu M, Ma S. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. J Atheroscler Thromb. 2021;28(12):1289-1297. doi: 10.5551/jat.59832
7. Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, Squire IB, et al. Pre-discharge risk stratification in unselected STE-MI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol. 2013;167(5):2182-8. doi: 10.1016/j.ijcard.2012.05.073
8. Barbarash O, Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Akbasheva O, et al. Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction. Ann Lab Med. 2016;36(4):313-9. doi: 10.3343/alm.2016.36.4.313
9. Yu J, Oh PC, Kim M, Moon J, Park YM, Lee K, et al. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. PLoS One. 2017;12(8):e0182829. doi: 10.1371/journal.pone.0182829
10. Liu N, Hang T, Gao X, Yang W, Kong W, Lou Q, et al. The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis. PLoS One. 2020;15(9):e0238775. doi: 10.1371/journal.pone.0238775
11. Gu L, Li J. Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis. Biosci Rep. 2019;39(6):BSR20182441. doi: 10.1042/BSR20182441
12. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25):2981-8. doi: 10.1161/01.cir.101.25.2981
13. Zhang T, Xu C, Zhao R, Cao Z. Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2021;8:697837. doi: 10.3389/fcvm.2021.697837
14. Sun Y, Pavey H, Wilkinson I, Fisk M. Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and metaanalysis. PLoS One. 2021;16(11):e0259026. doi: 10.1371/journal.pone.0259026
15. van den Berg VJ, Vroegindewey MM, Umans VA, van der Harst P, Asselbergs FW, Akkerhuis KM, et al. Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events. Biomarkers. 2022:1-6. doi: 10.1080/1354750X.2022.2032350. Epub ahead of print. PMID: 35078373
16. Magnussen C, Blankenberg S. Biomarkers for heart failure: small molecules with high clinical relevance. J Intern Med. 2018;283(6):530-543. doi: 10.1111/joim.12756
17. Jha D, Goenka L, Ramamoorthy T, Sharma M, Dhandapani VE, George M. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. Eur J Clin Invest. 2018;48(9):e12994. doi: 10.1111/eci.12994
18. Goenka L, Jha D, Sharma M, Dhandapani VE, George M. Factors which Influence the Levels of ST-2, Galectin-3 and MMP-9 in Acute Coronary Syndrome. Cardiovasc Hematol Disord Drug Targets. 2020;20(1):64-73. doi: 10.2174/1871529X19666190719104005
19. Gruson D, Lepoutre T, Ahn SA, Rousseau MF. Increased soluble ST2 is a stronger predictor of longterm cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol. 2014;172(1):250-2. doi: 10.1016/j.ijcard.2013.12.101
20. Pfetsch V, Sanin V, Jaensch A, Dallmeier D, Mons U, Brenner H, et al. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study. Cardiovasc Drugs Ther. 2017;31(2):167-177. doi: 10.1007/s10557-017-6718-1
21. Zhang Y, Fan Z, Liu H, Ma J, Zhang M. Correlation of plasma soluble suppression of tumorigenicity-2 level with the severity and stability of coronary atherosclerosis. Coron Artery Dis. 2020;31(7):628-635. doi: 10.1097/MCA.0000000000000851
22. Dieplinger B, Egger M, Haltmayer M, Kleber ME, Scharnagl H, Silbernagel G, et al. Increased soluble ST2 predicts longterm mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem. 2014;60(3):530-40. doi: 10.1373/clinchem.2013.209858
23. Luo G, Qian Y, Sheng X, Sun J, Wu Z, Liao F, et al. Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome. Front Cardiovasc Med. 2021;8:688522. doi: 10.3389/fcvm.2021.688522
24. Somuncu MU, Akgun T, Cakir MO, Akgul F, Serbest NG, Karakurt H, et al. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. J Atheroscler Thromb. 2019;26(11):970-978. doi: 10.5551/jat.48413
25. Chen B, Geng J, Gao SX, Yue WW, Liu Q. Eplerenone Modulates Interleukin-33/sST2 Signaling and IL-ip in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. J Interferon Cytokine Res. 2018;38(3):137-144. doi: 10.1089/jir.2017.0067
26. Lax A, Sanchez-Mas J, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 2015;3(1):50-58. doi: 10.1016/j.jchf.2014.07.015
27. Januzzi JL, Pascual-Figal D, Daniels LB. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol. 20i5;ii5(7 Suppl):70B-5B. doi: 10.1016/j.amjcard.2015.01.044
28. Maisel A, Xue Y, van Veldhuisen DJ, Voors AA, Jaarsma T, Pang PS, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol. 2014;114(5):737-42. doi: 10.1016/j.amjcard.2014.05.062. Erratum in: Am J Cardiol. 2014;114(10):1628. PMID: 25129066
29. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL Jr. Soluble concentrations of the interleukin receptor family member ST2 and в-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6(6):1206-13. doi: 10.1161/CIRCHEART-FAILURE.113.000457
Supplementary files
Review
For citations:
Fetisova V.I., Namitokov A.M., Gilevich I.V., Kosmacheva E.D. Soluble tumorigenicity suppression protein (sST2) as a possible biomarker in patients with acute coronary syndrome. South Russian Journal of Therapeutic Practice. 2023;4(2):7-17. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-2-7-17
Views:
907
Email this article 